Advertisement
Screener

Alkermes plc. (ALKS) Deferred Tax Assets, Tax Credit Carryforwards

Alkermes plc. Deferred Tax Assets, Tax Credit Carryforwards

Alkermes plc. (ALKS) had Deferred Tax Assets, Tax Credit Carryforwards of $22.93 million as of 2022-12-31, per its 10-K filed 2023-02-16.

Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Credit Carryforwards

us-gaap:DeferredTaxAssetsTaxCreditCarryforwards · last filed 2023-02-16

  • 2022-12-31: Deferred Tax Assets, Tax Credit Carryforwards $22.93M.
  • 2021-12-31: Deferred Tax Assets, Tax Credit Carryforwards $58.70M.
  • 2020-12-31: Deferred Tax Assets, Tax Credit Carryforwards $59.10M.
  • 2019-12-31: Deferred Tax Assets, Tax Credit Carryforwards $57.38M.
Period endDeferred Tax Assets, Tax Credit Carryforwards
2022-12-31$22.93M
10-K · filed 2023-02-16
2021-12-31$58.70M
10-K · filed 2023-02-16
2020-12-31$59.10M
10-K · filed 2022-02-16
2019-12-31$57.38M
10-K · filed 2021-02-11
2018-12-31$52.40M
10-K · filed 2020-02-13
2017-12-31$71.37M
10-K · filed 2019-02-15
2016-12-31$7.61M
10-K · filed 2018-02-16
2014-12-31$1.66M
10-K · filed 2015-02-24
2013-12-31$6.25M
10-K · filed 2015-02-24
2013-03-31$10.54M
10-KT · filed 2014-02-27
2012-03-31$12.29M
10-K · filed 2013-05-23
2011-03-31$18.04M
10-K · filed 2012-05-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Liquidia Corp (LQDA)United States$6.347B51.23
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76